A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated

NCT04716114 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: SKLB1028
DRUG: Salvage Chemotherapy

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.